Clinical trial
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
NCT01233505
Study timeline
Study start (unknown)2010-10-01Date precision: month
Registry last updated2014-04-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Adenocarcinoma of the Pancreasunresolved
Adenocarcinoma of the Stomachunresolved
BRCA1 Mutation Carrierunresolved
BRCA2 Mutation Carrierunresolved
Ovarian Mucinous Cystadenocarcinomaunresolved
Recurrent Breast Cancerunresolved
Recurrent Colon Cancerunresolved
Recurrent Gastric Cancerunresolved
Recurrent Ovarian Epithelial Cancerunresolved
Recurrent Ovarian Germ Cell Tumorunresolved
Recurrent Pancreatic Cancerunresolved
Recurrent Rectal Cancerunresolved
Stage IA Breast Cancerunresolved
Stage IB Breast Cancerunresolved
Stage II Breast Cancerunresolved
Stage IIIA Breast Cancerunresolved
Stage IIIB Breast Cancerunresolved
Stage IIIC Breast Cancerunresolved
Stage IV Breast Cancerunresolved
Stage IV Colon Cancerunresolved
Stage IV Gastric Cancerunresolved
Stage IV Ovarian Epithelial Cancerunresolved
Stage IV Ovarian Germ Cell Tumorunresolved
Stage IV Pancreatic Cancerunresolved
Stage IV Rectal Cancerunresolved
Interventions
veliparibDRUG
capecitabineDRUG · verified · RxNorm: capecitabine
oxaliplatinDRUG · verified · RxNorm: oxaliplatin
Sponsors & collaborators
National Cancer Institute (NCI)lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01233505 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.